|
An agreement was signed between Aventis and WHO in May 2001. Under the agreement,
Aventis donated US$25 million over five years, including the
drugs pentamidine, melarsoprol and eflornithine, to support
WHO activities in management and control of Human African
Trypanosomiasis, and in research and development of drugs.
Results obtained under this collaboration have been published
in the WHO Weekly Epidemiological Record: N° 8, 2006, 81,
69-80. The International Scientific Council for Trypanosomiasis
Research and Control at its meeting held in Addis Ababa stated:
'Considering the achievements made in the area of control
of sleeping sickness, leading to the current reduction of
new cases and increase of surveillance activities, the ISCTRC
recommends WHO to launch an elimination programme of sleeping
sickness, to adapt control strategies towards this goal and
advocate partners which have regularly provided support to
maintain their efforts and assistance'.
| 
